ADCT
ADC Therapeutics·NYSE
--
--(--)
--
--(--)
3.75 / 10
Netural
Fund flow assessment is positive at 7.49/10, indicating strong capital inflow despite negative trend signals across block, small, medium, large, and extra-large patterns. Analyst coverage is sparse with only one 'Strong Buy' rating from HC Wainwright & Co., and historical win rate is 0.0%, limiting conviction. The mismatch between rising price and pessimistic expectations adds uncertainty. Combined, the data suggest momentum traders could exploit fund inflows, but long-term investors should remain cautious.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-10-16
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate0.0%
What is the analyst consensus for ADCT?
- ADCT holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.75/10 (Netural).
